This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
Olaparib
From Proteopedia
(Difference between revisions)
| Line 4: | Line 4: | ||
<scene name='10/1001156/Overall/1'>Poly [ADP-ribose] polymerase 2 in complex with Olaparib</scene> ([[4tvj]]). | <scene name='10/1001156/Overall/1'>Poly [ADP-ribose] polymerase 2 in complex with Olaparib</scene> ([[4tvj]]). | ||
| + | See also: | ||
| + | *[[Mutations in BRCA1/BARD1 RING-domain heterodimer]] | ||
| + | *[[Mutations in Brca1 BRCT Domains]] | ||
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
<references/> | <references/> | ||
Revision as of 06:25, 19 October 2023
| |||||||||||
References
- ↑ Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JH, de Bono JS. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009 Jul 9;361(2):123-34. PMID:19553641 doi:10.1056/NEJMoa0900212
